RBC Bioscience

RBC Bioscience Forward P/E

The Forward P/E Ratio of RBC Bioscience (6848.TWO) as of Nov 5, 2026 is 10.66. In the previous year, Forward P/E Ratio was 35.74 — a change of -70.18% (lower).

Forward P/E

10.66

YoY

-70.18%

Last updated:

Forward P/E Ratio of RBC Bioscience is 2024 10.66 . Forward P/E Ratio of RBC Bioscience was 2023 35.74 . It decreases by -70.18% lower compared to the previous year.

The RBC Bioscience Forward P/E history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Forward P/E
Date
Forward P/E
Jan 1, 2018
16.78 TWD
Jan 1, 2019
15.90 TWD
Jan 1, 2020
1.62 TWD
Jan 1, 2021
8.00 TWD
Jan 1, 2022
60.83 TWD
Jan 1, 2023
35.74 TWD
Jan 1, 2024
10.66 TWD
The RBC Bioscience Forward P/E history
YEARForward P/EYoY
10.66-70.18%
35.74-41.24%
60.83+660.40%
8.00+393.94%
1.62-89.81%
15.90-5.26%
16.78—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

RBC Bioscience Stock analysis

What does RBC Bioscience do? RBC Bioscience Corp manufactures reagents and devices for life science and molecular diagnosis. The company's products include instruments equipped with ultraviolet sterilization systems for nucleic acid purification and disposable reagent strips and tips that work with built-in control programs for different nucleic acid extraction types. The firm developed nucleic acid purification reagents with cellulose-embedded magnetic beads to improve DNA and RNA purity for blood, bacteria, viruses, and forensic examinations. These products are used for future diagnosis, prevention, tracking, and treatment of diseases. The company sells its instruments and reagents to customers in life science and molecular diagnosis sectors. The instruments feature ultraviolet sterilization systems, while the reagents include disposable strips and tips with varying control programs. The reagents with cellulose-embedded magnetic beads are designed for high-purity nucleic acid extraction from diverse samples including blood, bacteria, viruses, and forensic materials. RBC Bioscience Corp's revenue comes from the sale of instruments and reagents. The instruments are sold to laboratories and medical facilities requiring nucleic acid purification systems. The reagents, including the disposable strips and tips, are sold alongside the instruments or separately for ongoing use in molecular diagnosis processes. RBC Bioscience is one of the most popular companies on Eulerpool.

Frequently Asked Questions about RBC Bioscience stock

Forward P/E Ratio of RBC Bioscience is 10.66 in 2024.

Forward P/E Ratio of RBC Bioscience changed from 35.74 to 10.66, representing a -70.18% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Forward P/E Ratio RBC Bioscience since 2006 – with annual values, charts, and detailed analysis.

The Forward P/E uses estimated future earnings to value a stock. A lower forward P/E relative to the trailing P/E suggests analysts expect earnings growth.

To evaluate Forward P/E Ratio's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Forward P/E Ratio.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Forward P/E Ratio's RBC Bioscience with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — RBC Bioscience

All Key Metrics — RBC Bioscience